These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges. Ahmed MH; Al-Atta A; Hamad MA Expert Opin Pharmacother; 2012 Sep; 13(13):1901-9. PubMed ID: 22770622 [TBL] [Abstract][Full Text] [Related]
3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
4. Management of metabolic complications and cardiovascular risk in HIV-infected patients. Blanco F; San Román J; Vispo E; López M; Salto A; Abad V; Soriano V AIDS Rev; 2010; 12(4):231-41. PubMed ID: 21179187 [TBL] [Abstract][Full Text] [Related]
5. Strategies for management and treatment of dyslipidemia in HIV/AIDS. Sax PE AIDS Care; 2006 Feb; 18(2):149-57. PubMed ID: 16338773 [TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. Maggi P; Di Biagio A; Rusconi S; Cicalini S; D'Abbraccio M; d'Ettorre G; Martinelli C; Nunnari G; Sighinolfi L; Spagnuolo V; Squillace N BMC Infect Dis; 2017 Aug; 17(1):551. PubMed ID: 28793863 [TBL] [Abstract][Full Text] [Related]
13. Systemic and cell-specific mechanisms of vasculopathy induced by human immunodeficiency virus and highly active antiretroviral therapy. Haser GC; Sumpio B J Vasc Surg; 2017 Mar; 65(3):849-859. PubMed ID: 26994951 [TBL] [Abstract][Full Text] [Related]
14. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice. Visnegarwala F; Maldonado M; Sajja P; Minihan JL; Rodriguez-Barradas MC; Ong O; Lahart CJ; Hasan MQ; Balasubramanyam A; White AC J Infect; 2004 Nov; 49(4):283-90. PubMed ID: 15474625 [TBL] [Abstract][Full Text] [Related]
15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
16. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Chapman MJ; Redfern JS; McGovern ME; Giral P Pharmacol Ther; 2010 Jun; 126(3):314-45. PubMed ID: 20153365 [TBL] [Abstract][Full Text] [Related]
17. Clinical management considerations for dyslipidemia in HIV-infected individuals. Kirchner JT Postgrad Med; 2012 Jan; 124(1):31-40. PubMed ID: 22314112 [TBL] [Abstract][Full Text] [Related]
18. Dyslipidemia: management using optimal lipid-lowering therapy. Ito MK Ann Pharmacother; 2012 Oct; 46(10):1368-81. PubMed ID: 23032652 [TBL] [Abstract][Full Text] [Related]
19. Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men. Floris-Moore M; Howard AA; Lo Y; Schoenbaum EE; Arnsten JH; Klein RS AIDS Patient Care STDS; 2007 Jul; 21(7):479-91. PubMed ID: 17651029 [TBL] [Abstract][Full Text] [Related]
20. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy. Calza L; Manfredi R; Pocaterra D; Chiodo F J Infect; 2008 Jul; 57(1):16-32. PubMed ID: 18358535 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]